---
schema_version: "secwatch.filing_event.v1"
accession: "0001790340-25-000133"
form_type: "8-K"
ticker: "IMRX"
cik: "0001790340"
company_name: "Immuneering Corp"
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:23:10.326053+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Immuneering Q3: 86% 9-month OS in pancreatic cancer; raised $225M; cash into 2029

## Summary
- Reported 86% overall survival at 9 months in first-line pancreatic cancer with atebimetinib + mGnP.
- Raised $225M in financing ($175M public offering + $25M Sanofi placement + $25M private placement).
- Cash and equivalents $227.6M as of Sep 30, 2025; cash runway extended into 2029.
- Granted US composition of matter patent for atebimetinib expiring 2042, with potential term extension.
- New case studies show complete response and conversion to curative-intent surgery with atebimetinib + FOLFIRINOX.

## SEC filing metadata
- accession: 0001790340-25-000133
- form_type: 8-K
- ticker: IMRX
- cik: 0001790340
- company_name: Immuneering Corp
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1790340/000179034025000133/0001790340-25-000133-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1790340/000179034025000133/imrx-20251112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001790340-25-000133
- JSON: https://secwatch.observer/filing/0001790340-25-000133.json
- Plain text: https://secwatch.observer/filing/0001790340-25-000133.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.